Tempus Announces Six Abstracts Accepted for Poster Presentation at the 2022 SABCS

Tempus Announces Six Abstracts Accepted for Presentation at the 2022 SITC Annual Meeting

Tempus Announces Six Abstracts Accepted for Presentation at the ASCO 2022

Tempus Announces Real-World Data-Driven Program to Accelerate Precision Oncology Research

GSK Announces Expanded Collaboration with Tempus in Precision Medicine to Accelerate R&D

Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics

Tempus Announces Collaboration with the COG to Expand Access to Genomic Testing

Tempus Announces Three Abstracts Accepted For Presentation at the ESMO

Tempus Announces Research Collaboration with Intermountain Healthcare to Advance Precision Oncology

Tempus Announces Sequencing Collaboration with Lilly to Expand Access to Genomic Testing

Tempus CE Marks Its Broad-Panel Genomic Sequencing and Algorithmic Diagnostic Tests

Tempus Announces 14 Abstracts Accepted For Presentation at the American Society of Clinical Oncology

Tempus to Launch Largest Clinically Available Liquid Biopsy Panel, xF+

Tempus Announces Agreement With the United States Department of Veterans Affairs National Precision

Tempus Announces Abstracts Accepted For Presentation at the American Association for Cancer Researc

Tempus’ Edge Platform Leverages Data & AI to Identify Therapeutic Options for Patients Earlier in th

Tempus Announces the Acquisition of Highline Sciences

Tempus Announces Open Enrollment for Study in Collaboration with GSK to Evaluate Niraparib in Advan

Tempus Announces Agreement with Janssen R&D to Leverage AI/ML and Real-World Evidence to Enhance the

Tempus Signs Strategic Collaboration Agreement with AstraZeneca to Advance Oncology Therapeutics